Vitrivax Announces Series A Financing To Further Demonstrate Feasibility Of Its Thermostable, Single-Dose Vaccine Technology, Aiming To Make Life-Saving Biologics Widely Accessible To Underserved Populations Globally
Vitrivax Announces Series A Financing To Further Demonstrate Feasibility Of Its Thermostable, Single-Dose Vaccine Technology, Aiming To Make Life-Saving Biologics Widely Accessible To Underserved Populations Globally
07/07/21, 11:22 AM
Location
boulderRound Type
series a
VitriVax, developer of a novel stabilization and delivery platform for vaccines and therapeutics, today announced it has closed its first institutional financing round with Adjuvant Capital. Series A proceeds will be used to develop and commercialize a technology with the potential to eliminate barriers to global vaccine administration, extending their life-saving benefits to underserved populations and compressing multidose regimens into a single shot.
Company Info
Location
boulder, colorado, united states
Additional Info
VitriVax is a Boulder, Colorado- and Boston, Massachusetts-based biotechnology company working to eliminate barriers to global vaccination. VitriVax partners with vaccine developers to formulate their vaccines to be thermostable and delivered in a single shot. Products formulated by the VitriVax ALTATM platform can be shipped globally without refrigeration or freezing, last for years on the shelf, and only require one patient interaction to deliver multiple doses. For more information, visit www.vitrivaxbio.com.